Are We There Yet? — Alternating Chemotherapy Regimens in Pancreatic Cancer
NEJM Evidence · 2024
DOI: 10.1056/evide2300341 ↗Kurz gefasst
Editorial in der Zeitschrift NEJM Evidence, 2024. Verfasst von Vaibhav Sahai und 1 weiteren Autor:innen. Beteiligte Einrichtung: Division of Hematology and Oncology, Department of Internal Medicine, University of Michigan, Ann Arbor, MI. Hauptthemen laut MEDLINE: Gemcitabine, Pancreatic Neoplasms. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 3 Literaturangaben.
Themen: Onkologische Pflege
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Division of Hematology and Oncology, Department of Internal Medicine, University of Michigan, Ann Arbor, MI.
- Division of Hematology and Oncology, Department of Medicine, Northwestern University, Chicago.
Zitieren
APA
Sahai, V., & Benson, A. B. (2024). Are We There Yet? — Alternating Chemotherapy Regimens in Pancreatic Cancer. NEJM Evidence. https://doi.org/10.1056/evide2300341
Vancouver
Sahai V, Benson AB. Are We There Yet? — Alternating Chemotherapy Regimens in Pancreatic Cancer. NEJM Evidence. 2024. doi:10.1056/evide2300341
BibTeX
@article{Sahai2024,
author = {Sahai, Vaibhav and Benson, Al B},
title = {Are We There Yet? — Alternating Chemotherapy Regimens in Pancreatic Cancer},
journal = {NEJM Evidence},
year = {2024},
doi = {10.1056/evide2300341}
}
EUVIMED